Year: 2021

Imaging Mass Cytometry Utilized to Seek Molecular Links between African Ancestry and Aggressive Forms of Breast and Prostate Cancer

Written by Customer Service on November 8, 2021. Posted in Public Companies.

IMC Studies Part of New York Genome Center’s Polyethnic-1000 Initiative Advancing Understanding of Racial Disparities in the Prevalence of Cancer Types SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Imaging Mass Cytometry™ (IMC™) is being utilized in studies led by researchers at Weill Cornell Medicine to identify molecular links between African ancestry and aggressive forms of breast and prostate cancer and investigate these as a source of racial disparities in cancer outcomes. The studies, Links between Ancestry and Outcome Disparity in Breast and Prostate Cancer Patients Across the African Diaspora in New York City, and Novel Complex Structural...

ReShape Lifesciences to Report Third Quarter 2021 Financial and Operational Results on Thursday, November 11, 2021

Written by Customer Service on November 8, 2021. Posted in Public Companies.

SAN CLEMENTE, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced today that it will report its third quarter 2021 financial and operational results on Thursday, November 11, 2021 at 8:30 a.m. ET. Management will post a webinar to discuss ReShape’s financial results at 8:45 a.m. ET that same day. The link to the webinar will be available on the Investor Relations page of the ReShape Lifesciences, Inc. website, https://ir.reshapelifesciences.com/. About ReShape Lifesciences Inc. ReShape Lifesciences™ is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved...

Gulf Resources (NASDAQ:GURE) Announces Conference Call to Discuss Historic Decision of Aligning Shareholders’ Interests with that of Management

Written by Customer Service on November 8, 2021. Posted in Public Companies.

SHOUGUANG, China, Nov. 08, 2021 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (Nasdaq: GURE) (“Gulf Resources”, “we,” or the “Company”), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced a conference call to discuss the new compensation program initiated by the Company to align the interests of its Chairman and senior management with that of its shareholders. For several years, the Company has been dissatisfied with its financial performance and with its inability to take cash from China to pay dividends and buy back shares. It has been seeking a way of attempting to align the interests of its shareholders with that of its management. The Company has created a new compensation program, that includes:The Chairman and top three executives repay...

Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit

Written by Customer Service on November 8, 2021. Posted in Public Companies.

Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a presentation on the company’s GEN-1 interleukin 12 (IL-12) immunotherapy program at the Cytokine-Based Cancer Immunotherapies Summit being held in Boston on November 30 to December 2, 2021. Dr. Answer will also be participating in two panel discussions. In his presentation, Dr. Anwer will be discussing how local delivery of IL-12 without significant systemic toxicity is feasible with a non-viral gene therapy approach that involves administration of...

Mason Graphite Releases Corporate Video

Written by Customer Service on November 8, 2021. Posted in Public Companies.

MONTRÉAL, Nov. 08, 2021 (GLOBE NEWSWIRE) — Mason Graphite Inc. (“Mason Graphite” or the “Company”) (TSX.V: LLG; OTCQX: MGPHF) is pleased to announce the release of a corporate video outlining its planned operation. The corporate video allows the viewer to envision the operation and evaluate its merit. It is expected to be used in different communications, corporate events, and visibility campaigns. The video has been posted to Mason Graphite’s website and can be directly accessed at: https://masongraphite.com/. About Mason Graphite Inc. Mason Graphite is a Canadian corporation dedicated to the production and transformation of natural graphite. Its strategy includes the development of value-added products, notably for green technologies like transport electrification. The Company also owns 100% of the rights to...

Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021

Written by Customer Service on November 8, 2021. Posted in Public Companies.

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021 before the open of US markets. Management will host a conference call on the same day at 8:30 a.m. ET. The conference call will be available via telephone by dialing toll free 1-844-200-6205 for U.S. callers; 1-646-904-5544 for local callers; or +1 929-526-1599 for international callers and using entry code 397367. An audio replay of the of the call will be available through November 18, 2021. A webcast of the call may be accessed from the “Events & Presentations”...

Alto Ingredients, Inc. Sells its Stockton Facility

Written by Customer Service on November 8, 2021. Posted in Mergers And Acquisitions.

Completes fuel-grade ethanol asset realignment Company is now term debt freeSACRAMENTO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer of specialty alcohols and essential ingredients, announced today it has sold its fuel ethanol production facility in Stockton, CA to Pelican Acquisition LLC for $24.0 million in cash, of which $16.2 million of the proceeds were used to retire the remaining portion of the company’s outstanding term debt. The company is now term debt free. Michael Kandris, Alto Ingredients’ president and CEO, stated, “With the sale of our Stockton facility, we have successfully completed the rationalization of our fuel-grade ethanol operations. The benefits of this effort are significant, improving the company’s profitability, strengthening our balance sheet,...

BIMI International Medical Inc. Signs MoU to Acquire Bengbu Mali Maternity Hospital

Written by Customer Service on November 8, 2021. Posted in Mergers And Acquisitions.

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) — BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a leading healthcare products and services provider, today announced that it has signed a Memorandum of Understanding (MoU) for the acquisition 100% interest of Bengbu Mali Maternity Hospital through BIMI’s common shares at the price of $3.00 per share. Bengbu Mali Maternity Hospital is a professional obstetrics and gynecology hospital, which provides services to around 30,000 patients per year. The hospital was founded in 2015, with outpatient and inpatient buildings totaling 24 floors. The profit of the hospital was $218,708 (RMB140,0000) in 2019 and predicted to be $937,324 (RMB 600,0000) in 2022. Bengbu Mali Maternity Hospital’s departments include internal medicine, obstetrics and gynecology, pediatrics, emergency...

Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Written by Customer Service on November 8, 2021. Posted in Public Companies.

Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patient screening and enrollment underway in Phase 1/2a study of pepinemab in Alzheimer’s disease Engaged in partnering discussions for a randomized Phase 3 trial in Huntington’s disease ROCHESTER, N.Y., Nov. 08, 2021 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. “We made steady progress on our pepinemab clinical programs since our last quarterly update. Enrollment is now underway in the Phase 1b/2 head and neck cancer...

Sanoma starts repurchasing own shares for its incentive programme

Written by Customer Service on November 8, 2021. Posted in Public Companies.

Sanoma Corporation, Stock Exchange Release, 8 November 2021 at 15:15 EET Sanoma starts repurchasing own shares for its incentive programme The Board of Directors of Sanoma Corporation has decided to start repurchasing the company’s own shares on the basis of the authorisation given by the 2021 Annual General Meeting. The shares shall be repurchased to be used as a part of the Company’s incentive programme. The maximum number of shares to be acquired is 361,000, corresponding to 0.22% of the total number of shares. The maximum sum to be used for the repurchase is EUR 6.0 million. The shares shall be acquired in public trading on Nasdaq Helsinki Ltd. at the market price prevailing at the time of purchase. The share repurchase shall start on 9 November 2021 at the earliest, and end by 30 June 2022, at the latest. The AGM held on 13 April...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals